A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

March 30, 2026

Study Completion Date

March 30, 2026

Conditions

Rheumatoid Arthritis

Interventions

DRUG

AZD6912

AZD6912 will be administered as a single sub-cutaneous dose.

DRUG

Placebo

Placebo will be administered as a single sub-cutaneous dose.

Trial Locations (2)

Research Site, Montreal

Research Site, Harrow